Ligand Pharmaceuticals traded at $276.98 this Tuesday September 15th, decreasing $3.67 or 1.31 percent since the previous trading session. Looking back, over the last four weeks, Ligand Pharmaceuticals lost 5.07 percent. Over the last 12 months, its price rose by 66.61 percent. Looking ahead, we forecast Ligand Pharmaceuticals to be priced at 278.38 by the end of this quarter and at 260.89 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.